Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-041614
Filing Date
2025-05-09
Accepted
2025-05-09 17:27:35
Documents
49
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0239143-10q_actinium.htm   iXBRL 10-Q 751811
2 CERTIFICATION ea023914301ex31-1_actinium.htm EX-31.1 9785
3 CERTIFICATION ea023914301ex31-2_actinium.htm EX-31.2 9824
4 CERTIFICATION ea023914301ex32-1_actinium.htm EX-32.1 3815
5 CERTIFICATION ea023914301ex32-2_actinium.htm EX-32.2 3854
6 GRAPHIC image_001.jpg GRAPHIC 119463
7 GRAPHIC image_002.jpg GRAPHIC 80255
8 GRAPHIC image_003.jpg GRAPHIC 54445
  Complete submission text file 0001213900-25-041614.txt   4227769

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE atnm-20250331.xsd EX-101.SCH 24106
10 XBRL CALCULATION FILE atnm-20250331_cal.xml EX-101.CAL 25061
11 XBRL DEFINITION FILE atnm-20250331_def.xml EX-101.DEF 133812
12 XBRL LABEL FILE atnm-20250331_lab.xml EX-101.LAB 298184
13 XBRL PRESENTATION FILE atnm-20250331_pre.xml EX-101.PRE 149359
51 EXTRACTED XBRL INSTANCE DOCUMENT ea0239143-10q_actinium_htm.xml XML 264010
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 25931824
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)